Morgan Brown

Chief Financial Officer at Clene Nanomedicine

Speaker

Mr. Morgan Brown has more than 33 years of finance and accounting experience with the last twenty-six years servicing biotechnology, pharmaceutical, medical device and clinical research companies. Mr. Brown is currently serving as the Chief Financial Officer of Clene Inc. (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Prior to joining Clene as CFO, Mr. Brown served in a similar capacity at Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company; at Innovus Pharmaceuticals, Inc. (OTCBB: INNV), an emerging pharmaceuticals company; at World Heart Corporation (NASDAQ: WHRT), a medical device company; at Lifetree Clinical Research, a clinical research organization; and, at NPS Pharmaceuticals Inc. (NASDAQ: NPSP), a biotechnology company. Previously he worked for KPMG LLP, an international public accounting firm, in Salt Lake City where he served as a Senior Audit Manager. Mr. Brown has participated in and led efforts to successfully evaluate, negotiate, and close transactions including equity and debt financings totaling over $1.5 billion and out-licensing of commercial stage asset transactions totaling $220 million. Mr. Brown has experience in sale-leaseback arrangements, facilities construction, and M&A activities. Mr. Brown is a licensed certified public accountant in the state of Utah. Mr. Brown earned a Master of Science degree in Business Administration from the University of Utah and a Bachelor of Science degree in Accounting from Utah State University.